Business Context and Reporting Period
SciSparc Ltd., a foreign private issuer based in Tel Aviv, Israel, filed Form 6-K on August 5, 2026. The report covers the month of August 2026 and primarily discloses a corporate development regarding its subsidiary, NeuroThera Labs.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a material event rather than a financial statement.
Material Changes
The primary material change disclosed is the launch of a Phase IIb clinical trial by the subsidiary NeuroThera Labs. The trial is being conducted at the Yale Child Study Center and focuses on a first-of-its-kind treatment for Tourette Syndrome.
Guidance, Outlook, and Risks
The filing incorporates by reference the "Forward-Looking Statements" section from the August 5, 2026 press release. No specific financial guidance, quantitative outlook, or detailed risk factors are explicitly detailed within the body of this Form 6-K text.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for details on the Phase IIb trial design and endpoints.
- Review the incorporated "Forward-Looking Statements" for specific risks associated with the clinical trial.
- Confirm the status of the Company's registration statements on Form F-3 and Form S-8 where this information is incorporated.
- Check subsequent filings for any updates on the trial's progress or financial impact.